Piperazine

Piperazine

SCHEMBL3769649

C1CNCCN1.C1CNCCNC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ESR1

The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 9/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
HIF1A Q16665 1/20 0.67
MAPT P10636 1/20 0.67
PDE4A P27815 1/20 0.67
KDR P35968 1/20 0.67
ALDH1A1 P00352 1/20 0.64
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
CYP2C9 P11712 1/20 0.40
MEN1 O00255 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
ADRA2C P18825 1/20 0.35
CCR2 P41597 1/20 0.35
CXCL12 P48061 1/20 0.35
BLM P54132 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4287153 1.00 CXCR4 (1.00) CXCR4SMN1; SMN2HIF1AMAPTPDE4A
SCHEMBL22199 1.00 CXCR4 (1.00) CXCR4SMN1; SMN2HIF1AMAPTPDE4A
SCHEMBL33477 1.00 CXCR4 (1.00) CXCR4SMN1; SMN2HIF1AMAPTPDE4A
SCHEMBL8503965 1.00 CXCR4 (1.00) CXCR4SMN1; SMN2HIF1AMAPTPDE4A
SCHEMBL3998680 1.00 CXCR4 (1.00) CXCR4SMN1; SMN2HIF1AMAPTPDE4A
SCHEMBL18585750 1.00 CXCR4 (1.00) CXCR4SMN1; SMN2HIF1AMAPTPDE4A
SCHEMBL576838 1.00 CXCR4 (1.00) CXCR4SMN1; SMN2HIF1AMAPTPDE4A
SCHEMBL9947670 1.00 CXCR4 (1.00) CXCR4SMN1; SMN2HIF1AMAPTPDE4A
SCHEMBL577659 1.00 CXCR4 (1.00) CXCR4SMN1; SMN2HIF1AMAPTPDE4A
SCHEMBL935211 1.00 CXCR4 (1.00) CXCR4SMN1; SMN2HIF1AMAPTPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11525074-B2 Two-component curing adhesive, laminated film, laminated film-manufacturing apparatus, and method for manufacturing laminated film DIC CORPORATION (JP) 2022-12-13 US claimed
EP-4397492-A1 ADHESIVE, LAYERED BODY, METHOD FOR MANUFACTURING LAYERED BODY, AND PACKAGING MATERIAL DIC Corporation (JP) 2024-07-10 EP disclosed
CN-118234771-A Adhesive, laminate, and packaging material DIC株式会社 2024-06-21 CN disclosed
CN-118234824-A Adhesive, laminate, method for producing laminate, and packaging material DIC株式会社 2024-06-21 CN disclosed
WO-2024095572-A1 COATING COMPOSITION AND COATING FILM 日本ペイント・インダストリアルコーティングス株式会社 2024-05-10 WO disclosed
CN-117730130-A Adhesive, laminate, method for producing laminate, and packaging material DIC株式会社 2024-03-19 CN disclosed
CN-117715999-A Adhesive, laminate, method for producing laminate, and packaging material DIC株式会社 2024-03-15 CN disclosed
EP-2966135-B1 ANTICORROSIVE COATING COMPOSITION, ANTICORROSIVE COATING FILM, AND METHOD FOR PREVENTING CORROSION OF BASE MATERIAL CHUGOKU MARINE PAINTS (JP) 2024-02-21 EP disclosed
CN-117043289-A Coating composition 日涂工业涂料有限公司 2023-11-10 CN disclosed
EP-3385072-B1 ANTIFOULING COMPOSITE COATING FILM, ANTIFOULING SUBSTRATE, AND METHOD FOR MANUFACTURING ANTIFOULING SUBSTRATE CHUGOKU MARINE PAINTS (JP) 2023-09-06 EP disclosed
EP-1689393-A2 PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2006-08-16 EP disclosed
US-20050197328-A1 Imidazopyridine derivatives as kinase inhibitors GLAXO GROUP LIMITED (GB) 2005-09-08 US disclosed
US-20050153978-A1 Medicaments GLAXO GROUP LIMITED (GB) 2005-07-14 US disclosed
WO-2005037198-A2 PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-04-28 WO disclosed
EP-1490367-A1 IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-29 EP disclosed
EP-1487441-A2 BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-22 EP disclosed
WO-2003080610-A1 IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-10-02 WO disclosed
WO-2003080125-A2 BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-10-02 WO disclosed
US-20020165221-A1 Mediators of hedgehog signaling pathways, compositions and uses related thereto CURIS, INC. 2002-11-07 US disclosed
US-3950451-A COUPLED PRODUCT OF ALKYLPHENOL AND PHENOL-FORMALDEHYDE-DIAMINE CONDENSATE ASAHI DENKA KOGYO K.K. (JA) 1976-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197328-A1 Imidazopyridine derivatives as kinase inhibitors NR4A3, XDH, MAPK8 CXCR4 124/4885SMN1; SMN2 3075/4885HIF1A 1362/4885
US-20050153978-A1 Medicaments GRK1, ROCK1, GRK7 CXCR4 976/4885SMN1; SMN2 1495/4885HIF1A 2156/4885
US-20020165221-A1 Mediators of hedgehog signaling pathways, compositions and uses related thereto SHH, SMO, GLI1 CXCR4 1591/4885SMN1; SMN2 4587/4885HIF1A 871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.